As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
|Articles|June 1, 2016
- Pharmaceutical Executive-06-01-2016
- Volume 36
- Issue 6
Pharmaceutical Executive, June 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive June 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 10 years ago
Pharm Exec's Top 50 Companies 2016over 10 years ago
Diversity and Inclusion: A Pharma 50 Perspectiveover 10 years ago
Design that Deliversover 10 years ago
A Digital Prescription for the Pharma Industryover 10 years ago
Science Meets Art: Mapping the Topography of MSover 10 years ago
Pharma and Biotech Financial Outlook: Hazyover 10 years ago
Promises and Pitfalls in Calculating Drug Valueover 10 years ago
Europe’s ‘Radical’ Regulators Drawn Further into Pricing Debateover 10 years ago
Country Report: ItalyAdvertisement
Related to this article
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Advertisement
Advertisement
Trending on PharmExec
1
The Next Biopharma Revolution: Quantum Computing
2
Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific
3
How Medications like XOCOVA Prevent Illness After Exposure to COVID-19
4
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
5